Noah D Kauff

Author PubWeight™ 43.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009 3.89
2 American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol 2014 3.07
3 Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007 2.20
4 Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002 2.16
5 The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 2011 2.09
6 Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 2004 1.63
7 Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol 2009 1.62
8 BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004 1.61
9 Genome-wide association studies of cancer. J Clin Oncol 2010 1.45
10 Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 2011 1.32
11 SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010 1.27
12 Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. Gynecol Oncol 2003 1.23
13 Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 2011 1.15
14 Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila) 2011 1.10
15 Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer 2013 1.04
16 Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer 2011 1.01
17 Genome-wide association studies of cancer predisposition. Hematol Oncol Clin North Am 2010 0.97
18 Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. Cancer Epidemiol Biomarkers Prev 2006 0.96
19 Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer 2004 0.91
20 Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. Clin Cancer Res 2002 0.90
21 Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer? J Clin Oncol 2008 0.87
22 Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecol Oncol 2012 0.86
23 Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. Curr Opin Oncol 2011 0.84
24 How should women with early-onset endometrial cancer be evaluated for lynch syndrome? J Clin Oncol 2007 0.82
25 Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. Breast Cancer Res Treat 2010 0.80
26 Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. Gynecol Oncol 2009 0.80
27 Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations. J Clin Oncol 2009 0.79
28 The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy. Gynecol Oncol 2006 0.79
29 Screening for familial ovarian cancer: a ray of hope and a light to steer by. J Clin Oncol 2012 0.78
30 Laparoscopic bilateral salpingo-oophorectomy in breast cancer patients after transverse rectus abdominus myocutaneous flap reconstructive surgery. Gynecol Oncol 2005 0.78
31 Does a BRCA mutation plus tamoxifen equal hysterectomy? Gynecol Oncol 2007 0.78
32 Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes. Am J Surg Pathol 2016 0.77
33 Screening and prevention of hereditary gynecologic cancers. Semin Oncol 2007 0.77
34 Modeling genetic risk of breast cancer. JAMA 2007 0.77
35 Surgical risk-reduction in carriers of BRCA mutations: where do we go from here? Gynecol Oncol 2004 0.77
36 Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol 2011 0.76
37 Reducing the risk of gynecologic cancer in the Lynch syndrome. N Engl J Med 2006 0.76
38 Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. Breast Cancer Res Treat 2014 0.75
39 ATR mutations in endometrial cancer: a window into the role of mismatch repair defects. J Clin Oncol 2009 0.75